|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gamarra-Luques CD, Hapon MB, Goyeneche AA
and Telleria CM: Resistance to cisplatin and paclitaxel does not
affect the sensitivity of human ovarian cancer cells to
antiprogestin-induced cytotoxicity. J Ovarian Res. 7:452014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sekita S, Yoshihira K, Natori S, Udagawa
S, Muroi T, Sugiyama Y, Kurata H and Umeda M: Mycotoxin production
by Chaetomium spp. and related fungi. Can J Microbiol.
27:766–772. 1981. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hauser D, Weber HP and Sigg HP: Isolation
and configuration of Chaetocin. Helv Chim Acta. 53:1061–1073.
1970.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu X, Guo S, Liu X and Su L: Chaetocin
induces endoplasmic reticulum stress response and leads to death
receptor 5-dependent apoptosis in human non-small cell lung cancer
cells. Apoptosis. 20:1499–1507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Isham CR, Tibodeau JD, Jin W, Xu R, Timm
MM and Bible KC: Chaetocin: A promising new antimyeloma agent with
in vitro and in vivo activity mediated via imposition of oxidative
stress. Blood. 109:2579–2588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lai YS, Chen JY, Tsai HJ, Chen TY and Hung
WC: The SUV39H1 inhibitor chaetocin induces differentiation and
shows synergistic cytotoxicity with other epigenetic drugs in acute
myeloid leukemia cells. Blood Cancer J. 5:e3132015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Isham CR, Tibodeau JD, Bossou AR, Merchan
JR and Bible KC: The anticancer effects of chaetocin are
independent of programmed cell death and hypoxia, and are
associated with inhibition of endothelial cell proliferation. Br J
Cancer. 106:314–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dixit D, Ghildiyal R, Anto NP and Sen E:
Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and
JNK-dependent inhibition of glucose metabolism. Cell Death Dis.
5:e12122014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee YM, Lim JH, Yoon H, Chun YS and Park
JW: Antihepatoma activity of chaetocin due to deregulated splicing
of hypoxia-inducible factor 1α pre-mRNA in mice and in vitro.
Hepatology. 53:171–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaib H, Nebbioso A, Prebet T, Castellano
R, Garbit S, Restouin A, Vey N, Altucci L and Collette Y:
Anti-leukemia activity of chaetocin via death receptor-dependent
apoptosis and dual modulation of the histone methyl-transferase
SUV39H1. Leukemia. 26:662–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Truitt L, Hutchinson C, DeCoteau JF and
Geyer CR: Chaetocin antileukemia activity against chronic
myelogenous leukemia cells is potentiated by bone marrow stromal
factors and overcomes innate imatinib resistance. Oncogenesis.
3:e1222014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vo MC, Nguyen-Pham TN, Lee HJ, Jung SH,
Choi NR, Hoang MD, Kim HJ and Lee JJ: Chaetocin enhances dendritic
cell function via the induction of heat shock protein and cancer
testis antigens in myeloma cells. Oncotarget. 8:46047–46056. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han X, Han Y, Zheng Y, Sun Q, Ma T, Zhang
J and Xu L: Chaetocin induces apoptosis in human melanoma cells
through the generation of reactive oxygen species and the intrinsic
mitochondrial pathway, and exerts its anti-tumor activity in vivo.
PLoS One. 12:e1759502017.
|
|
16
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cotter TG: Apoptosis and cancer: The
genesis of a research field. Nat Rev Cancer. 9:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferrin G, Linares CI and Muntané J:
Mitochondrial drug targets in cell death and cancer. Curr Pharm
Des. 17:2002–2016. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong Y, Cao A, Shi J, Yin P, Wang L, Ji G,
Xie J and Wu D: Tangeretin, a citrus polymethoxyflavonoid, induces
apoptosis of human gastric cancer AGS cells through extrinsic and
intrinsic signaling pathways. Oncol Rep. 31:1788–1794. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roy J, Galano JM, Durand T, Le Guennec JY
and Lee JC: Physiological role of reactive oxygen species as
promoters of natural defenses. FASEB J. 31:3729–3745. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holmström KM and Finkel T: Cellular
mechanisms and physiological consequences of redox-dependent
signalling. Nat Rev Mol Cell Biol. 15:411–421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
D'Autréaux B and Toledano MB: ROS as
signalling molecules: Mechanisms that generate specificity in ROS
homeostasis. Nat Rev Mol Cell Biol. 8:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reuter S, Gupta SC, Chaturvedi MM and
Aggarwal BB: Oxidative stress, inflammation, and cancer: How are
they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Galadari S, Rahman A, Pallichankandy S and
Thayyullathil F: Reactive oxygen species and cancer paradox: To
promote or to suppress? Free Radic Biol Med. 104:144–164. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weng MS, Chang JH, Hung WY, Yang YC and
Chien MH: The interplay of reactive oxygen species and the
epidermal growth factor receptor in tumor progression and drug
resistance. J Exp Clin Cancer Res. 37:612018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tafani M, Sansone L, Limana F, Arcangeli
T, De Santis E, Polese M, Fini M and Russo MA: The interplay of
reactive oxygen species, hypoxia, inflammation, and sirtuins in
cancer initiation and progression. Oxid Med Cell Longev.
2016:39071472016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zou P, Xia Y, Ji J, Chen W, Zhang J, Chen
X, Rajamanickam V, Chen G, Wang Z, Chen L, et al: Piperlongumine as
a direct TrxR1 inhibitor with suppressive activity against gastric
cancer. Cancer Lett. 375:114–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raj L, Ide T, Gurkar AU, Foley M, Schenone
M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al:
Selective killing of cancer cells by a small molecule targeting the
stress response to ROS. Nature. 475:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He J, Chen X, Li B, Zhou W, Xiao J, He K,
Zhang J and Xiang G: Chaetocin induces cell cycle arrest and
apoptosis by regulating the ROS-mediated ASK-1/JNK signaling
pathways. Oncol Rep. 38:2489–2497. 2017. View Article : Google Scholar : PubMed/NCBI
|
